


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: HU et al.

Application Serial No.: 09/935,726

Filing Date: August 24, 2001

Title: Vascular Endothelial Growth Factor 2



Art Unit: 1647

Examiner: To be assigned

Atty. Dkt No.: PF112P3D1C1

**RESPONSE TO NOTICE TO FILE CORRECTED
APPLICATION PAPERS AND NOTICE TO COMPLY**

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Notice to File Corrected Application Papers (Formalities Letter Confirmation No. 3533) mailed on December 4, 2001 requesting substitute drawings, and sequence listing in compliance with §§ 1.821-1.825, Applicants submit herewith: (a) a Fee Transmittal; (b) a Substitute Sequence Listing in paper (pages 1-20) and computer-readable (diskette) forms; (c) Statement Under 37 C.F.R. §§ 1.825(a)-(b); (d) 47 Sheets of Substitute Drawings containing Figures 1A-29, (e) Information Disclosure Statement, Form PTO/SB/08, references AA-FO and 13 Statutory Declarations and accompanying exhibits; and (f) a Copy of Notice to File Corrected Application Papers. Please amend the application as follows.

AVAILABLE COPY